Clinical Trial Update: A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of GW572016 (lapatinib) in advanced or metastatic non-small cell lung cancer; the trial was terminated with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Non-Small Cell | Phase 2 | Status: TERMINATED | Results posted: 2010-01-06